Lemtrada

Type: Product

Name: Lemtrada

First reported May 15 2013 - Updated May 15 2013 - 2 reports

Campath slash Lemtrada for relapsing-remitting multiple sclerosis

Campath was chemotherapy medication used in the fighting of chronic lymphocytic leukemia and was used as an off-brand, chemotherapy-type therapy for helping those with multiple sclerosis (MS) as well.It was a little less than 3 years... ... [Published Examiner.com - May 15 2013]

Entities: Campath, Lemtrada, Multiple Sclerosis

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Investment Research Group

Catalysts and core growth

May 02nd 2013 - today published a report on BTG (BTG.L, LSE:BTG, LON:BTG) entitled "Catalysts And Core Growth". In summary, the report says:BTG is entering a critical 12-month period marked by multiple catalysts involving its lead internal programmes ... [Published Stockopedia - May 02 2013]

Entities: Catalyst, Lemtrada, Investment Research Group

First reported Apr 10 2013 - Updated Apr 10 2013 - 1 reports

Biogen Idec Inc

Annette Funicello’s death raises MS awareness

PrintEmail Comments (0)The death this week of actress and one-time Disney “Mouseketeer” Annette Funicello from complications of multiple sclerosis raised the specter of a debilitating disease and the need for further research to one day find a cure.“It ... [Published Boston Herald - Apr 10 2013]

Entities: Multiple Sclerosis, Annette Funicello, Biogen Idec Inc, Lemtrada, Avonex

First reported Mar 22 2013 - Updated Mar 22 2013 - 1 reports

Anthera Pharmaceuticals Inc

4 Healthcare Stock Stories for Weekend Wellness

Sanofi-Aventis ( NYSE:SNY ): Current price $50.71 Late Thursday, France’s number-one drugmaker reported that its experimental Lemtrada remained effective in patients suffering from multiple sclerosis during the first year of an extension study. Relapse ... [Published Wall St. Cheat Sheet - Mar 22 2013]

Entities: Anthera Pharmaceuticals Inc, Lemtrada, Baxter International Inc, European Medicines Agency, defibrotide

First reported Mar 13 2013 - Updated Mar 13 2013 - 1 reports

Genzyme Corp

Genzyme’s Multiple Sclerosis Franchise Featured at AAN Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced today that data from its AUBAGIO® (teriflunomide) and LEMTRADATM (alemtuzumab) multiple sclerosis clinical development programs will be presented during ... [Published Yahoo! Finance - Mar 13 2013]

Entities: Aubagio, Genzyme Corp, Multiple Sclerosis

First reported Jan 29 2013 - Updated Jan 29 2013 - 1 reports

FDA Food & Drug Administration

FDA accepts Genzyme Lemtrada biologics license application for review

The US FDA has accepted Genzyme Lemtrada (alemtuzumab) biologics license application (sBLA) for review for relapsing multiple sclerosis (RMS). ... [Published PBR - News - Jan 29 2013]

Entities: Lemtrada, Biologics License Application, Genzyme Corp, FDA Food & Drug Administration

First reported Jan 29 2013 - Updated Jan 29 2013 - 1 reports

Alemtuzumab

US FDA accepts for review of Genzymeâs Lemtrada sBLA for relapsing multiple sclerosis treatment

The US Food and Drug Administration (FDA) has accepted for review the Genzyme's supplemental Biologics License Application (sBLA) file seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS). The company also ... [Published PharmaBiz - Jan 29 2013]

Entities: Multiple Sclerosis, Lemtrada, Alemtuzumab, Genzyme Corp, Aubagio

First reported Jan 29 2013 - Updated Jan 29 2013 - 1 reports

4 Healthcare Stock Stories Not to be Missed

Sanofi-Aventis ( NYSE:SNY ): Closing price $48.92 Sanofi’s subsidiary Genzyme says that the FDA has accepted for review its supplemental Biologics License Application file requesting approval of Lemtrada (alemtuzumab) for treating relapsing multiple ... [Published Wall St. Cheat Sheet - Jan 29 2013]

Entities: Idenix Pharmaceuticals Inc, CytRx Corporation, doxorubicin, Health Care, Sanofi SA

Quotes

(live-PR.com) - GlobalData has released its new Country report, "PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022" . Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neur...

Market Report, "PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 20 ... [Published Live-PR.com - May 02 2013]

"I think many people will be comfortable with taking a pill BID [i e., dimethyl fumarate], said Edward Fox, MD, director of the Multiple Sclerosis Clinic of Central Texas, "For some, [the choice] may be related to how often they have to think about their disease. There are some things not captured in trials. And one of those is patient perception."

MS Choices Grow: What's Best for Your Patient? [Published MedPage Today - Apr 20 2013]

More Content

sort by: Date \| Relevance
2 Healthcare Companies With Recent Intensive In... [Published Seeking Alpha - May 16 2013]
PharmaPoint Analysis: Multiple Sclerosis - US D... [Published Individual.com - May 16 2013]
Campath slash Lemtrada for relapsing-remitting ... [Published Examiner.com - May 15 2013]
Research and Markets: Lemtrada (Multiple Sclero... [Published Business Wire Professional Services News - May 15 2013]
Lemtrada (Multiple Sclerosis) - Forecast and Ma... [Published Individual.com - May 15 2013]
PharmaPoint: Multiple Sclerosis - US Drug Forec... [Published KOTA Territory News - May 14 2013]
Investment Research Weekly Roundup including: N... [Published Proactiveinvestors United Kingdom RSS feed - May 03 2013]
Market Report, "PharmaPoint: Multiple Sclerosis... [Published Live-PR.com - May 02 2013]
Catalysts and core growth [Published Stockopedia - May 02 2013]
Infinata's BioPharm Insight to Host Educational... [Published Zecco - Apr 22 2013]
MS Choices Grow: What's Best for Your Patient? [Published MedPage Today - Apr 20 2013]
Annette Funicello’s death raises MS awareness [Published Boston Herald - Apr 10 2013]
4 Healthcare Stock Stories for Weekend Wellness [Published Wall St. Cheat Sheet - Mar 22 2013]
Effect of Genzyme’s LEMTRADA™ Maintained in Pat... [Published Business Wire Health News - Mar 21 2013]
Genzyme’s Multiple Sclerosis Franchise Featured... [Published Yahoo! Finance - Mar 13 2013]
Deals Of The Weeks Wonders If A Biopharma Super... [Published The IN VIVO Blog - Feb 01 2013]
FDA accepts Genzyme Lemtrada biologics license ... [Published PBR - News - Jan 29 2013]
US FDA accepts for review of Genzymeâs Lemtrada... [Published PharmaBiz - Jan 29 2013]
4 Healthcare Stock Stories Not to be Missed [Published Wall St. Cheat Sheet - Jan 29 2013]
Genzyme’s LEMTRADA™ (alemtuzumab) Application f... [Published EON Health & Medicine - Jan 28 2013]
Genzyme’s LEMTRADA™ (alemtuzumab) Application f... [Published Business Wire Science: Science News - Jan 28 2013]
Genzyme’s LEMTRADA™ (alemtuzumab) Application f... [Published Business Wire Health News - Jan 28 2013]
Genzyme to present data from clinical developme... [Published PharmaBiz - Oct 09 2012]
Trends in Multiple Sclerosis Therapy Examined i... [Published PRWeb - Oct 02 2012]
Sanofi's Aubagio to Square Off Against MS Injec... [Published Pharmaceutical Executive - Sep 13 2012]
i3 Analytics’ ClinicalTrials Navigator Sees A N... [Published PRWeb - Sep 13 2012]
US FDA issues refuse to file letter to Genzeme'... [Published PharmaBiz - Aug 28 2012]